277 related articles for article (PubMed ID: 26503317)
21. Gingival overgrowth in Pompe disease: a case report.
de Gijt JP; van Capelle CI; Oosterhuis JW; van der Ploeg AT; van der Wal KG
J Oral Maxillofac Surg; 2011 Aug; 69(8):2186-90. PubMed ID: 21783002
[TBL] [Abstract][Full Text] [Related]
22. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
23. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
[TBL] [Abstract][Full Text] [Related]
24. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature.
Malhotra K; Carrington DC; Liebeskind DS
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e172-e175. PubMed ID: 28647415
[TBL] [Abstract][Full Text] [Related]
25. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
[TBL] [Abstract][Full Text] [Related]
26. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
Tan QK; Cheah SM; Dearmey SM; Kishnani PS
Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
[TBL] [Abstract][Full Text] [Related]
27. [Guidelines for monitoring late-onset Pompe disease.Sociedad Española de Medicina Interna (SEMI), Sociedad Española de Neurología (SEN) y Sociedad Española de Neumología y CirugíaTorácica (SEPAR)].
Gutiérrez-Rivas E; Illa I; Pascual-Pascual SI; Pérez-López J; Vílchez-Padilla JJ; Bautista-Lorite J; Barrot E; López de Munain A; ; ;
Rev Neurol; 2015 Apr; 60(7):321-8. PubMed ID: 25806482
[TBL] [Abstract][Full Text] [Related]
28. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
Bernstein DL; Bialer MG; Mehta L; Desnick RJ
Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
[TBL] [Abstract][Full Text] [Related]
29. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
30. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
[TBL] [Abstract][Full Text] [Related]
31. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.
Chien YH; Lee NC; Peng SF; Hwu WL
Pediatr Res; 2006 Sep; 60(3):349-52. PubMed ID: 16857770
[TBL] [Abstract][Full Text] [Related]
32. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
Kishnani PS; Nicolino M; Voit T; Rogers RC; Tsai AC; Waterson J; Herman GE; Amalfitano A; Thurberg BL; Richards S; Davison M; Corzo D; Chen YT
J Pediatr; 2006 Jul; 149(1):89-97. PubMed ID: 16860134
[TBL] [Abstract][Full Text] [Related]
33. [Adult form of Pompe disease].
Ziółkowska-Graca B; Kania A; Zwolińska G; Nizankowska-Mogilnicka E
Pneumonol Alergol Pol; 2008; 76(5):396-9. PubMed ID: 19003770
[TBL] [Abstract][Full Text] [Related]
34. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease.
Doerfler PA; Nayak S; Herzog RW; Morel L; Byrne BJ
Clin Immunol; 2015 Jun; 158(2):140-7. PubMed ID: 25842186
[TBL] [Abstract][Full Text] [Related]
35. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy.
Hossain MA; Miyajima T; Akiyama K; Eto Y
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193
[TBL] [Abstract][Full Text] [Related]
36. [Myopathy associated with respiratory insufficiency: diagnostic difficulties in adult-onset Pompe disease].
Merkli H; Pál E; Nagy F; Horváth R; Várdi VK; Komoly S; Illés Z
Orv Hetil; 2006 Jul; 147(30):1421-4. PubMed ID: 16977780
[TBL] [Abstract][Full Text] [Related]
37. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
38. SWORD: A simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease.
Gallay L; Petiot P; Durieu I; Streichenberger N; Berard F
Neuromuscul Disord; 2016 Nov; 26(11):801-804. PubMed ID: 27637292
[TBL] [Abstract][Full Text] [Related]
39. Fractures in children with Pompe disease: a potential long-term complication.
Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease).
Rohman PJ; Scott E; Richfield L; Ramaswami U; Hughes DA
J Obstet Gynaecol Res; 2016 Oct; 42(10):1263-1271. PubMed ID: 27384519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
